Oncology

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the dose limiting toxicities observed among patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.

ET and CT are used as standard maintenance therapy for HR-positive and HER-negative MBC in clinical practice, and there was no prospective study data on which is better, according to the study authors.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses the reasons that the use of second-generation tyrosine kinase inhibitors in patients with chronic-phase CML who have failed one or more second-generation tyrosine kinase inhibitors needed further investigation.

Helen Thackray, MD, dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.

Helen Thackray, MD, provides a brief overview and highlights of the RESET clinical trial.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the response rates and survival outcomes were for ponatinib among patients who failed second-generation tyrosine kinase inhibitors in the OPTIC trial.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the implications of the results of his research on further investigation and treatment opportunities for patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the noteworthy results observed in the study in relation to cause of death among patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the issues existing around prior data on the causes of death for patients with polycythemia vera (PV) and why it was important to have greater clarity in this area.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the common treatments for patients with polycythemia vera.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the survival estimates for patients with polycythemia vera in the past and the mortality rates among these patients.

Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on what polycythemia vera (PV) is and why it was important to understand mortality and causes of death among patients with PV.

New research identifies patients most at risk of continuing problems with medulloblastoma, which can be applied immediately in medical clinics.

Study indicates pure CBD was able to reduce cell viability in 3 of the 6 cell lines and that this effect was cell line specific rather than specific to certain cancers.

Targeted therapies often have better toxicity profiles, allowing patients to remain adherent and stay on medications longer.

FDA approves Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

Patients with relapsed/refractory leukemia and lymphomas generally have a grim prognosis, which has paved the way for immunotherapy treatments.

Further, the findings suggest that cancer survivors are also likely to be at an increased risk of severe coronavirus disease 2019 (COVID-19) outcomes, given that both influenza and COVID-19 are both epidemic respiratory viruses.

FDA grants fast track designation to irinotecan liposome injection (Onivyde; MM-398) as second-line monotherapy for patients with small cell lung cancer whose disease progressed following a platinum-based chemotherapy regimen.

Investigators hope discovery will lead to new treatments for pancreatic cancer.

Pralsetinib (Gavreto) approved for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer.

Medicaid expansion was associated with a 2% drop in cancer mortality, a recent study found.

The FDA has granted a breakthrough therapy designation to zanidatamab for the treatment of patients with HER2 gene–amplified biliary tract cancer who have received prior therapy.

The new optical sensing method is based on multi-pass spectroscopy and can detect the presence of 1 molecule of formaldehyde in a million air particles, or 1 part per million, even in the presence of gasses that often interfere with optical measurements.

How has COVID-19 impacted our professional lives in providing care to patients with cancer, who are at even greater risk of contracting the virus and more likely to have higher morbidity and mortality should they be infected?

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Although cancer deaths with the highest death rates per capita accounted for the greatest number of years lost, the study authors said cancers that typically occur in younger populations had a disproportionate share of the burden.

Pharmacists can play an integral role in educating patients with breast cancer to improve health outcomes.